We observed the sensitivity of PTPN11-mutated NCI-H661 NSCLC cells to growth inhibition by the PI3K inhibitor copanlisib and the MEK inhibitor refametinib. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.